A quarter of U.S. biotechs are considering shifting away from their current Chinese suppliers, though only 2% have done so.July 5, 2024Check out STAT+Sponsored By Adobe STAT+ | Report shows U.S. biotechs are wary of Chinese partnerships due to looming BIOSECURE Act A survey by China-based L.E.K. Consulting found a looming anti-China biotechnology bill has spooked U.S. life sciences companies. By John Wilkerson GSK buys mRNA-based Covid, flu vaccines from CureVac in restructured partnership CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK. By Adam Feuerstein STAT+ | Regulating artificial intelligence doesn't have to be complicated, some experts say Experts highlighted strategies the government already uses to regulate different industries as models for writing new rules to regulate AI. By Brittany Trang More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Cancer Briefing? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments